企業プロフィール
Moderna, Inc. 株価・ニュース・カタリスト
- ティッカー:
- MRNA
- 取引所:
- NASDAQ
- セクター:
- Nucleic Acid Drugs
- 所在地:
- United States
株価パフォーマンス
188.94 USD (-1.89%)
終値
最終更新: 2026年10月1日
18.1B USD
時価総額
株価変動の要因
2026年10月1日 時点で MRNA は 1.89% 下落し、$188.94 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Messenger RNA Medicines Platform
Moderna is a biotechnology company built around messenger RNA medicines. Its platform combines mRNA sequence design, lipid nanoparticle delivery, automated research, clinical development, and large-scale manufacturing to create vaccines and therapeutics across infectious disease, oncology, and rare disease.
Commercial Respiratory Vaccines
The commercial portfolio is anchored by Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus. Moderna is extending this respiratory franchise through seasonal influenza and combination vaccines intended to address multiple respiratory viruses with a single injection.
Broad Infectious-Disease Pipeline
Beyond its marketed products, Moderna is developing vaccines against influenza, cytomegalovirus, norovirus, and other viral pathogens. The company uses a common platform and manufacturing infrastructure across these programs, allowing clinical and process-development knowledge to be reused across vaccine candidates.
Oncology and Individualized Therapies
Moderna's oncology portfolio includes intismeran autogene, an individualized neoantigen therapy being developed with Merck in combination with KEYTRUDA. The broader cancer pipeline applies mRNA to encode tumor-specific antigens, immune stimulators, and other proteins intended to generate or strengthen antitumor immune responses.
Rare-Disease Therapeutics
The company is also developing systemic mRNA therapeutics for inherited metabolic diseases, including programs designed to restore missing intracellular enzymes. These candidates extend the platform beyond prophylactic vaccines into repeat-dose medicines for genetically defined disorders.
今後のカタリスト
- FDA PDUFA decision for seasonal influenza vaccine candidate mFLUSIVA on August 5, 2026.
- Enrollment of an additional Phase 3 cohort for norovirus vaccine candidate mRNA-1403 following the interim analysis.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。